Thrombocytopenia — low platelet count: GP workup and red flags

What a low platelet count means

Finding a low platelet count on a routine full blood count (FBC) is a common scenario in Australian general practice. Thrombocytopenia is defined as a platelet count below 150 × 10⁹/L. The severity classification guides urgency:

Severity	Platelet count	Clinical significance
Mild	100–149 × 10⁹/L	Usually asymptomatic; may be artefactual
Moderate	50–99 × 10⁹/L	Increased bruising; usually safe for minor procedures
Severe	20–49 × 10⁹/L	Significant mucocutaneous bleeding risk
Very severe	Below 20 × 10⁹/L	Spontaneous bleeding risk including intracranial haemorrhage

The differential diagnosis spans the entirely benign (artefactual EDTA-induced clumping) to the immediately life-threatening (thrombotic thrombocytopenic purpura, acute leukaemia). Systematic triage determines which clinical pathway applies.

The RCPA Manual and Therapeutic Guidelines — Haematology emphasise that thrombocytopenia should never be assumed benign without a methodical first-step assessment.

A. Core clinical — the AU general-practice framework

First-step triage: five questions

1. Is the count real?

EDTA (the anticoagulant in standard purple-top blood tubes) causes platelet clumping in approximately 1 in 1,000 samples, producing a falsely low count on the automated analyser. Repeat the FBC in a citrate (blue-top) tube. Call the haematology lab and request a blood film review — platelet clumps are visible under the microscope. If the repeat count normalises, pseudothrombocytopenia is confirmed and no further workup is needed.

2. Is the patient bleeding?

Assess bleeding severity using the ISTH Bleeding Score. Sites to ask about: petechiae, purpura, bruising beyond the threshold of minor trauma, bleeding from gums, heavy menstrual bleeding, blood in urine or stool, epistaxis, haemoptysis. Ask about current anticoagulant or antiplatelet medication — these amplify bleeding risk at any platelet count.

3. Could this be a thrombotic microangiopathy emergency?

The blood film is the most important test in this context. Schistocytes (red cell fragments) on the blood film, combined with low platelets plus haemolysis (raised LDH, low haptoglobin, anaemia), is a haematological emergency — possible TTP, HUS, HELLP, or DIC. Same-day haematology assessment is required. Do not wait for ADAMTS13 results to initiate transfer.

4. Is the patient on heparin?

Any heparin use — including low-molecular-weight heparin, unfractionated heparin flushes, or heparin within the prior 100 days — combined with a platelet count drop of ≥50% from baseline raises HIT (heparin-induced thrombocytopenia) as a diagnosis. The 4T scoring system (Timing of platelet fall relative to heparin, degree of Thrombocytopenia, Thrombosis or other sequelae, alternative aetiologies) stratifies pre-test probability. High-probability 4T score: stop heparin immediately and switch to a non-heparin anticoagulant while awaiting anti-PF4-heparin antibody testing. Do not wait for the antibody result before stopping heparin in a high-probability case.

5. Is the patient pregnant?

Always perform a urine or serum β-hCG in any woman of reproductive age with thrombocytopenia. Gestational thrombocytopenia (the most common pregnancy-related cause), pre-eclampsia with HELLP syndrome, and acute fatty liver of pregnancy all present with low platelets and require different management pathways.

History to take

• Drug history — heparin (doses, dates), valproate, quinine (including in tonic water), vancomycin, sulfonamides, beta-lactams, NSAIDs, supplements (fish oil, ginkgo, garlic), recent chemotherapy or immunotherapy (immune checkpoint inhibitors), COVID vaccination (VITT — adenoviral vector vaccines, relevant for historical cases)
• Systemic symptoms — fever, weight loss, night sweats, lymphadenopathy, fatigue (haematological malignancy)
• Autoimmune history — lupus, Sjögren’s syndrome, antiphospholipid syndrome, thyroid disease
• Infection history — HIV risk, HCV exposure, recent viral illness, overseas travel (dengue in north Queensland or tropics, malaria)
• Alcohol intake — liver disease and hypersplenism
• Family history — inherited platelet disorders

Examination

• Vital signs — fever, hypotension, tachycardia (sepsis, TMA)
• Skin — petechiae, purpura, wet purpura in mouth (very severe thrombocytopenia), jaundice
• Lymph nodes — lymphadenopathy raises lymphoma or infection
• Spleen — splenomegaly suggests liver disease, haematological malignancy, or portal hypertension
• Neurological — new confusion or focal deficit with low platelets and haemolysis points to TTP

B. What the blood film tells you — urgent red flags

The RCPA Manual defines blood film morphology as the most information-rich single investigation in the workup of thrombocytopenia. Phone the laboratory to request a film if one has not been reported.

Film finding	Diagnosis to pursue	Urgency
Schistocytes (red cell fragments)	Thrombotic microangiopathy (TTP, HUS, DIC, HELLP, malignant hypertension)	Same-day haematology or ED
Blasts	Acute leukaemia	Same-day haematology or ED
Tear-drop cells + leucoerythroblastic	Marrow infiltration (myelofibrosis, metastatic cancer)	Urgent haematology
Plasma cells + rouleaux	Myeloma	Urgent haematology
Hypersegmented neutrophils + oval macrocytes	B12 or folate deficiency (megaloblastic pancytopenia)	Outpatient
Atypical lymphocytes + lymphocytosis	CLL (older adult) or infectious mononucleosis (younger patient)	Outpatient referral
Platelet clumps, otherwise normal	Pseudothrombocytopenia — repeat in citrate tube	Reassurance

C. Common causes and their management

Immune thrombocytopenia (ITP)

ITP is isolated thrombocytopenia without identifiable cause (primary) or secondary to SLE, HIV, HCV, HBV, H. pylori, CLL, or lymphoma. The FBC otherwise shows no other abnormality and the blood film shows no fragments or blasts.

Per ASH 2019 guidelines (Neunert et al.) and Provan et al. 2019 international consensus:

• Platelets ≥30 × 10⁹/L without bleeding — observation is appropriate in most patients; treatment is not automatically required
• First-line treatment when needed — prednisolone 1 mg/kg/day for 2–4 weeks (PBS general schedule), or dexamethasone 40 mg/day for 4 days
• When rapid response is needed — intravenous immunoglobulin (IVIG via National Blood Authority criteria) raises platelets within 24–48 hours
• Second-line — thrombopoietin receptor agonists (eltrombopag [Revolade] or romiplostim [Nplate], PBS Authority Required, specialist-prescribed), rituximab, splenectomy

Secondary ITP: investigate for and treat the underlying cause — H. pylori eradication, hepatitis C treatment, HIV management.

Heparin-induced thrombocytopenia (HIT)

Per ASH 2018 guidelines (Cuker et al.) and Greinacher NEJM 2015:

• Platelet drop ≥50% from baseline 5–10 days after starting heparin (or earlier on re-exposure within 100 days)
• HIT is prothrombotic — patients develop clots (PE, DVT, arterial thrombosis), not bleeding
• Intermediate or high 4T score: stop heparin immediately, start alternative anticoagulant (fondaparinux off-label, argatroban, or danaparoid via specialist)
• Never give platelet transfusion in HIT — it fuels the prothrombotic state
• HIT antibody (anti-PF4-heparin) testing confirms diagnosis — but do not delay stopping heparin awaiting results in high-probability cases

Thrombotic microangiopathy — TTP

TTP causes microangiopathic haemolytic anaemia (MAHA) plus thrombocytopenia. The classic triad on investigation is: schistocytes on film, raised LDH, low haptoglobin. ADAMTS13 activity below 10% confirms TTP.

Per ISTH 2020 guidelines (Zheng et al.) and HSANZ:

• Mortality untreated approaches 90%; treated with urgent plasma exchange survival exceeds 80%
• Transfer to a tertiary centre immediately — plasma exchange must not be delayed
• Caplacizumab adjunct (via SAS or specialist approval) reduces time to platelet recovery
• Avoid platelet transfusion in TTP

Drug-induced thrombocytopenia

Review all medications, herbal supplements, and recent vaccinations. The commonest culprits: valproate, quinine (including in tonic water — ask specifically), vancomycin, sulfonamides, beta-lactams, GPIIb/IIIa inhibitors, immune checkpoint inhibitors. Stop the causative agent. Recovery is usually within 5–10 days.

Bone marrow failure

Bicytopenia or pancytopenia plus thrombocytopenia raises concern for aplastic anaemia, myelodysplastic syndrome, acute leukaemia, lymphoma, or metastatic malignancy infiltrating the marrow. Blasts on the blood film are a haematological emergency. Any pancytopenia requires urgent bone marrow examination via haematology.

B12 and folate deficiency causes megaloblastic pancytopenia — macrocytic anaemia plus mild thrombocytopenia and leucopenia, with hypersegmented neutrophils and oval macrocytes on film. Corrects with B12 or folate replacement (see b12-folate-deficiency).

Infection-related

HIV can cause thrombocytopenia at any disease stage and may be the presenting feature. HCV, HBV, EBV, and CMV are other causes. In travellers returning from tropical regions, dengue (including north Queensland) and malaria are important. Offer HIV, HBV, and HCV serology in any patient with unexplained thrombocytopenia.

D. Australian operations

MBS pathology items

Key items for thrombocytopenia workup per MBS Online:

• Item 65070 — FBC
• Item 71089 — blood film morphology pathologist review
• Item 65072 — reticulocyte count
• Item 65120 — coagulation panel (PT, aPTT, fibrinogen)
• Item 65126 — D-dimer
• Item 66838 — B12
• Item 66602 — folate and iron studies
• Items for ANA, dsDNA, antiphospholipid screen, HIV/HBV/HCV serology — Medicare-rebatable

ADAMTS13 activity and anti-PF4-heparin antibody testing are performed at tertiary haematology or immunohaematology laboratories, typically ordered by and billed via the specialist.

PBS — haematological treatments

• Prednisone and dexamethasone — PBS general schedule, no Authority
• Eltrombopag (Revolade) — PBS Authority Required (Streamlined); chronic ITP refractory to first-line; specialist-prescribed
• Romiplostim (Nplate) — PBS Authority Required; chronic ITP; specialist-prescribed
• IVIG (intravenous immunoglobulin) — National Blood Authority criteria; restricted indications; approved for acute severe ITP or peri-procedure
• Rituximab — often via hospital or private pathway for ITP; PBS Authority for other indications
• Caplacizumab (Cablivi) — limited Australian access; tertiary SAS approval for TTP
• Eculizumab (Soliris) — PBS Authority for atypical HUS (complement-mediated)

Referral pathways

Per HSANZ and Therapeutic Guidelines:

• Same-day haematology or ED — platelets below 20 × 10⁹/L with or without bleeding; suspected TTP, HIT, acute leukaemia, aplastic anaemia; pregnant patient with falling platelets, haemolysis, or hypertension
• Urgent public haematology outpatient (2–4 weeks) — persistent unexplained thrombocytopenia, suspected MDS or lymphoma, bicytopenia
• Obstetric haematology — pregnancy-related thrombocytopenia, ITP in pregnancy, peripartum platelet planning
• National Blood Authority — IVIG approvals

E. Special populations

Pregnancy

Gestational thrombocytopenia is the most common cause of thrombocytopenia in pregnancy — typically mild (platelets usually ≥70 × 10⁹/L), third-trimester onset, normal LFTs and renal function, resolves post-partum. No treatment is needed.

Pre-eclampsia with HELLP (Haemolysis, Elevated Liver enzymes, Low Platelets) is an obstetric emergency. TTP can present or worsen during pregnancy, often peri-partum. Antiphospholipid syndrome causes recurrent thrombocytopenia alongside miscarriage or thrombosis. Any pregnant patient with platelets falling below 100 × 10⁹/L or with haemolysis or abnormal liver function requires urgent obstetric or haematology review.

Older adults

Unexplained thrombocytopenia in adults over 60 warrants a lower threshold for bone marrow examination — the yield for MDS and lymphoma is higher than in younger adults. New thrombocytopenia in this age group should not be assumed to be ITP without marrow assessment.

Aboriginal and Torres Strait Islander peoples

Higher prevalence of some inherited haemoglobin conditions (thalassaemia trait, haemoglobin variants) that may coexist with acquired thrombocytopenia. Culturally safe specialist referral through Aboriginal Medical Services partnerships is important. Screen for HBV and HCV given higher community prevalence.

Children

Acute immune thrombocytopenia in children aged 2–10 following viral illness is typically self-limiting — 80% resolve within three months without treatment. Observation is usually appropriate. Chronic ITP in children may require specialist paediatric haematology input.

When to escalate

Refer same-day to haematology or emergency department if:

• Platelet count below 20 × 10⁹/L — or below 50 × 10⁹/L with active bleeding
• Schistocytes on blood film with haemolysis — suspect TTP or HUS; initiate transfer for plasma exchange without delay
• Blasts on blood film — acute leukaemia
• High-probability HIT — stop heparin, start alternative anticoagulant, urgent haematology
• Fever plus thrombocytopenia — sepsis plus DIC pathway; suspect severe infection
• New neurological symptoms or renal failure with thrombocytopenia and haemolysis — TTP until proven otherwise
• Pregnant patient with falling platelets plus hypertension or haemolysis — obstetric emergency

Refer urgently (within 1–2 weeks) for: persistent unexplained thrombocytopenia after initial workup, bicytopenia or pancytopenia, lymphadenopathy or splenomegaly, constitutional symptoms (weight loss, night sweats, fatigue).

What this article is and is not

This is general health information drawn from Australian clinical resources — Therapeutic Guidelines — Haematology, HSANZ, RCPA Manual, RACGP, and NPS MedicineWise — and international guidelines including ASH 2019 ITP guidelines and ISTH 2020 TTP guidelines. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about investigation, diagnosis, and treatment are made with your own GP and treating specialists.

For consumer resources: HealthDirect — Blood disorders, Better Health Channel, Leukaemia Foundation Australia.

---

Sources cited

1. Therapeutic Guidelines: Haematology — thrombocytopenia
2. RCPA Manual — FBC and blood film interpretation
3. HSANZ — Haematology Society of Australia and New Zealand
4. RACGP
5. NPS MedicineWise
6. HealthDirect Australia
7. Neunert C et al. ASH 2019 guidelines for ITP. Blood Adv 2019;3:3829
8. Provan D et al. Updated international consensus on ITP. Blood Adv 2019;3:3780
9. Cuker A et al. ASH 2018 guidelines for HIT. Blood Adv 2018;2:3360
10. Greinacher A. Heparin-induced thrombocytopenia. NEJM 2015;373:252
11. Zheng XL et al. ISTH guidelines for TTP. J Thromb Haemost 2020;18:2486
12. MBS Online — pathology items